Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Gains from Investment Securities (2016 - 2025)

Fortress Biotech (FBIO) has 12 years of Gains from Investment Securities data on record, last reported at $540000.0 in Q2 2025.

  • For Q2 2025, Gains from Investment Securities changed 0.0% year-over-year to $540000.0; the TTM value through Jun 2025 reached $540000.0, changed 0.0%, while the annual FY2024 figure was $188000.0, 441.82% up from the prior year.
  • Gains from Investment Securities reached $540000.0 in Q2 2025 per FBIO's latest filing, roughly flat from $540000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $993000.0 in Q4 2021 and bottomed at -$604000.0 in Q4 2022.
  • Average Gains from Investment Securities over 5 years is $128625.0, with a median of $25000.0 recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: tumbled 980.0% in 2023, then skyrocketed 21500.0% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $993000.0 in 2021, then tumbled by 160.83% to -$604000.0 in 2022, then skyrocketed by 93.71% to -$38000.0 in 2023, then soared by 292.11% to $73000.0 in 2024, then surged by 639.73% to $540000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $540000.0 in Q2 2025, $540000.0 in Q1 2025, and $73000.0 in Q4 2024.